Of note, enhanced phosphorylation of AKT was demonstrated by the treatment of breast and prostate cancer cell lines with capivasertib as a consequence of the protein being held in a hyperphosphorylated but catalytically inactive form following compound binding [36]. This evidence concerns the gene AKT1 and Familial prostate cancer.